摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

苯甲酸乙酐 | 29285-17-4

中文名称
苯甲酸乙酐
中文别名
——
英文名称
benzoylacetate
英文别名
3-Oxo-3-phenylpropionate;3-oxo-3-phenylpropanoate
苯甲酸乙酐化学式
CAS
29285-17-4
化学式
C9H7O3
mdl
——
分子量
163.153
InChiKey
HXUIDZOMTRMIOE-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    57.2
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:b82b689164e2964d6afbb305a8eec42b
查看

反应信息

  • 作为反应物:
    描述:
    苯甲酸乙酐 为溶剂, 生成 苯乙酮
    参考文献:
    名称:
    PqsBC,铜绿假单胞菌喹诺酮信号的生物合成中的一种缩合酶:晶体结构,抑制作用和反应机理。
    摘要:
    铜绿假单胞菌产生许多烷基喹诺酮类次生代谢产物,以其抗菌作用和参与细胞间通讯而闻名。在烷基喹诺酮生物合成途径中,β-酮酰基-(酰基载体蛋白)合酶III(FabH)像酶PqsBC一样催化辛酰基辅酶A和2-氨基苯甲酰乙酸酯(2-ABA)的缩合形成信号分子2-庚基- 4(1H)-喹诺酮。PqsBC是潜在的药物靶标,因其异二聚体排列和不同于经典FabH样酶的活性位点而独特。考虑到亚基之间的序列差异,一个关键的问题是两个亚基如何相对于活性位点进行组织。在这项研究中,PqsBC结构被确定为2A分辨率,揭示PqsB和PqsC具有伪2倍对称性,出乎意料地模仿FabH同型二聚体。PqsC具有由Cys129和His269组成的活性位点,周围的活性位点裂口具有疏水性,约为相关FabH酶体积的两倍,这可能是容纳芳香族底物2-ABA所必需的。从生理和动力学研究中,我们确定了2-氨基苯乙酮是PqsBC的一种途径固有的竞
    DOI:
    10.1074/jbc.m115.708453
  • 作为产物:
    描述:
    二氧化碳苯乙酮 在 bis(tetra-n-butylammonium) tetrakis(benzenethiolato-μ3-sulfidoiron) 3 A molecular sieve 、 亚硝酸四乙基铵 作用下, 以 乙腈 为溶剂, 生成 苯甲酸乙酐
    参考文献:
    名称:
    Carbon Dioxide Fixation Coupled with Nitrite Reduction, Catalyzed by 4Fe4S Cluster
    摘要:
    在CO2饱和的CH3CN中,采用控制电位电解法,在−1.25 V相对于SCE的条件下,以(Bu4N)2[Fe4S4(SPh)4]催化的(Et4N)NO2的还原反应,结合PhCOCH3作为质子源和分子筛3A作为脱水剂,不仅催化生成少量N2O作为N2的前体,还生成了PhCOCH2COO−。
    DOI:
    10.1246/cl.1987.1951
点击查看最新优质反应信息

文献信息

  • Carbon Dioxide Fixation Coupled with Nitrite Reduction, Catalyzed by 4Fe4S Cluster
    作者:Koji Tanaka、Ryuhei Wakita、Toshio Tanaka
    DOI:10.1246/cl.1987.1951
    日期:1987.10.5
    The reduction of (Et4N)NO2 catalyzed by (Bu4N)2[Fe4S4(SPh)4] in the presence of PhCOCH3 and Molecular Sieves 3A as a proton source and a dehydration agent, respectively, under the controlled potential electrolysis at −1.25 V vs. SCE in CO2-saturated CH3CN catalytically produced not only N2 with a small amount of N2O as a precursor of N2 but also PhCOCH2COO−.
    在CO2饱和的CH3CN中,采用控制电位电解法,在−1.25 V相对于SCE的条件下,以(Bu4N)2[Fe4S4(SPh)4]催化的(Et4N)NO2的还原反应,结合PhCOCH3作为质子源和分子筛3A作为脱水剂,不仅催化生成少量N2O作为N2的前体,还生成了PhCOCH2COO−。
  • Electrochemical Carboxylation of Ketones RCOCH<sub>2</sub>R′ Coupled with CO<sub>2</sub>Reduction by [Ru(bpy)<sub>2</sub>(CO)<sub>2</sub>]<sup>2+</sup>
    作者:Koji Tanaka、Hajime Miyamoto、Toshio Tanaka
    DOI:10.1246/cl.1988.2033
    日期:1988.12.5
    Electrochemical carboxylation of PhCOCH3 and C6H10(O) coupled with CO2 reduction by [Ru(bpy)2(CO)2]2+ was carried out in CO2−saturated dry CH3CN. CO2 ligated on the ruthenium atom is reduced to HCOO− or CO upon the electrochemical reduction of the complex, where PhCOCH3 and C6H10(O) function as a proton source, and the resultant carbanions react with CO2 to afford the corresponding ketoacids, catalytically
    PhCOCH3 和 C6H10(O) 的电化学羧化与 [Ru(bpy)2(CO)2]2+ 对 CO2 的还原作用在 CO2-饱和干燥 CH3CN 中进行。结合在钌原子上的 CO2 在复合物的电化学还原过程中被还原为 HCOO− 或 CO,其中 PhCOCH3 和 C6H10(O) 作为质子源,产生的碳负离子与 CO2 反应以催化提供相应的酮酸。
  • KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES
    申请人:Flynn Daniel L.
    公开号:US20080269267A1
    公开(公告)日:2008-10-30
    Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, a disease caused by c-Met kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by a Raf kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.
    本发明的化合物可用于治疗哺乳动物癌症,特别是人类癌症,包括但不限于恶性黑色素瘤、实体肿瘤、胶质母细胞瘤、卵巢癌、胰腺癌、前列腺癌、肺癌、乳腺癌、肾癌、肝癌、宫颈癌、原发肿瘤部位的转移、骨髓增生性疾病、慢性髓细胞白血病、白血病、乳头状甲状腺癌、非小细胞肺癌、间皮瘤、高嗜酸性综合征、胃肠道间质瘤、结肠癌、眼部疾病,其特征是过度增殖导致失明,包括各种视网膜病变、糖尿病性视网膜病变、类风湿性关节炎、哮喘、慢性阻塞性肺疾病、肥大细胞增多症、肥大细胞白血病、由c-Abl激酶引起的疾病、其致癌形式、异常融合蛋白和多态体,由c-Kit激酶引起的疾病、其致癌形式、异常融合蛋白和多态体,由c-Met激酶引起的疾病、其致癌形式、异常融合蛋白和多态体,或由Raf激酶引起的疾病、其致癌形式、异常融合蛋白和多态体。
  • THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS
    申请人:MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    公开号:US20160130241A1
    公开(公告)日:2016-05-12
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.
    本文提供的是I式化合物,以及其药学上可接受的盐,其中代换基如规范中所披露。这些化合物及其所含的药物组合物,可用于治疗退行性疾病和障碍。
  • ATP-Dependent Carboxylation of Acetophenone by a Novel Type of Carboxylase
    作者:Björn Jobst、Karola Schühle、Uwe Linne、Johann Heider
    DOI:10.1128/jb.01423-09
    日期:2010.3
    ABSTRACT

    Anaerobic ethylbenzene metabolism in the betaproteobacterium Aromatoleum aromaticum is initiated by anaerobic oxidation to acetophenone via ( S )-1-phenylethanol. The subsequent carboxylation of acetophenone to benzoylacetate is catalyzed by an acetophenone-induced enzyme, which has been purified and studied. The same enzyme is involved in acetophenone metabolism in the absence of ethylbenzene. Acetophenone carboxylase consists of five subunits with molecular masses of 70, 15, 87, 75, and 34 kDa, whose genes ( apcABCDE ) form an apparent operon. The enzyme is synthesized at high levels in cells grown on ethylbenzene or acetophenone, but not in cells grown on benzoate. During purification, acetophenone carboxylase dissociates into inactive subcomplexes consisting of the 70-, 15-, 87-, and 75-kDa subunits ( apcABCD gene products) and the 34-kDa subunit ( apcE gene product), respectively. Acetophenone carboxylase activity was restored by mixing the purified subcomplexes. The enzyme contains 1 Zn 2+ ion per αβγδ core complex and is dependent on the presence of Mg 2+ or Mn 2+ . In spite of the presence of Zn in the enzyme, it is strongly inhibited by Zn 2+ ions. Carboxylation of acetophenone is dependent on ATP hydrolysis to ADP and P i , exhibiting a stoichiometry of 2 mol ATP per mol acetophenone carboxylated. The enzyme shows uncoupled ATPase activity with either bicarbonate or acetophenone in the absence of the second substrate. These observations indicate that both substrates may be phosphorylated, which is consistent with isotope exchange activity observed with deuterated acetophenone and inhibition by carbamoylphosphate, a structural analogue of carboxyphosphate. A potential mechanism of ATP-dependent acetophenone carboxylation is suggested.

    摘要 厌氧乙苯代谢中的倍增菌 芳香菌 中的厌氧乙苯代谢是通过( S )-1-苯乙醇氧化成苯乙酮。随后,苯乙酮在一种苯乙酮诱导酶的催化下羧化成苯甲酰乙酸酯。在没有乙苯的情况下,这种酶也参与苯乙酮的代谢。苯乙酮羧化酶由五个亚基组成,其分子质量分别为 70、15、87、75 和 34 kDa,其基因(apcABCDE apcABCDE ) 构成一个明显的操作子。该酶在乙苯或苯乙酮生长的细胞中合成水平较高,但在苯甲酸盐生长的细胞中合成水平较低。在纯化过程中,苯乙酮羧化酶会解离成由 70、15、87 和 75 kDa 亚基组成的非活性亚复合物(apcABCD、apcABCDE 和 apcABCDE)。 基因产物 基因产物)和 34 kDa 亚基(apcE apcE 基因产物)组成。通过混合纯化的亚复合物可恢复乙酰苯醌羧化酶的活性。该酶含有 1 Zn 2+ 离子,并且依赖于 Mg 2+ 或 Mn 2+ .尽管酶中含有 Zn,但它受到 Zn 2+ 离子的强烈抑制作用。苯乙酮的羧化依赖于 ATP 水解为 ADP 和 P i 显示出每摩尔苯乙酮羧化 2 摩尔 ATP 的化学计量。在没有第二种底物的情况下,无论是碳酸氢盐还是苯乙酮,该酶都显示出非偶联 ATP 酶活性。这些观察结果表明,两种底物都可能被磷酸化,这与在使用氘化苯乙酮时观察到的同位素交换活性以及氨基甲酰基磷酸(一种羧基磷酸的结构类似物)的抑制作用是一致的。提出了一种潜在的依赖 ATP 的苯乙酮羧化机制。
查看更多